Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania.
about
Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signaturesQuantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoringMultiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.Impact of neoadjuvant chemotherapy on breast reconstructionLocoregional therapy of locally advanced breast cancer: a clinical practice guideline.Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.Docetaxel in the treatment of breast cancer: current experience and future prospects.Locoregional therapy of breast cancer: maximizing control, minimizing morbidity.Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese PopulationMastectomy for management of breast cancer in Ibadan, NigeriaNeoadjuvant chemotherapy for early breast cancer.Primary therapy in breast cancer: what have we learned from landmark trials?Clinical overview of metronomic chemotherapy in breast cancer.Recent Advances in the Neoadjuvant Treatment of Breast Cancer.Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response.Anti-Phosphohistone H3-Positive Mitoses Are Linked to Pathological Response in Neoadjuvantly Treated Breast Cancer.Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer.Intra-arterial interventional therapy for inoperable local advanced breast cancer: A retrospective study.Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient.Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy.Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy.
P2860
Q24812541-2907FCFB-5DE2-4ADE-AD79-B54B0E0AD4E6Q25257743-07B06F88-A385-4F7E-BFB7-9F910B35352CQ34616067-C28130A2-4F71-4CFE-9AFE-765B291B0C90Q35190289-B73F9CE4-6161-4990-9C78-A07B59481F3AQ35239625-AC5C864F-4E94-4C0A-A727-3BE3FECF3A9EQ35832458-2A617710-C372-480F-BC23-6843A6716012Q36235546-9396D0A4-1027-4DB0-A965-6ECE3B6751ABQ36614002-C7612E78-425D-494D-98AF-5E7ABE30752CQ36891801-142D0576-C7AB-434C-A2EC-3229702DC3D4Q37425883-CBCA5003-0B8D-49FF-AC2B-1BF57FA23C7CQ37510892-2D535BE3-ABA2-4226-B909-BB68AAA02A4DQ38155673-D7B7C422-45B5-43BF-9A02-89F15480AF46Q38560651-7BDC5047-9D84-46D0-BE35-9E95655E5E4DQ38687392-8895354E-7922-487E-9AD1-53F34756DFFCQ39221924-6A263BBE-3241-42E3-ABD6-7FB071B18E3FQ41201081-EDC3AB1C-B929-476A-B673-A763534A30C7Q42926176-FC483EF8-C6EC-4644-8C14-59294A482DCEQ45234165-880123EF-CFF0-4C95-9A83-C6A0ACDD2B9DQ45962835-9D615558-C1D3-42B8-931E-2B4AC9AA2812Q47717315-C7AF20BE-E5AB-4168-9D96-4024D3F0473DQ47995601-E3669E02-317F-4789-974A-0C039D075330Q48476561-FB9A485C-268C-4780-AA13-577F49C8FCF8Q49744785-76FE7727-8DC4-4018-B9F0-BD91B7CB7D43Q50243933-75F02A53-A72E-4B27-9DDC-F923A73F5FC2Q53015150-829EEC73-D70B-40BB-9735-113C4B4E3770Q54337477-AAE5003F-1858-4EFC-9797-9BC28977B424Q54967714-226FA2F7-C44A-4685-A71D-8D1CA11EB2F7
P2860
Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Proceedings of the consensus c ...... 3, Philadelphia, Pennsylvania.
@ast
Proceedings of the consensus c ...... 3, Philadelphia, Pennsylvania.
@en
type
label
Proceedings of the consensus c ...... 3, Philadelphia, Pennsylvania.
@ast
Proceedings of the consensus c ...... 3, Philadelphia, Pennsylvania.
@en
prefLabel
Proceedings of the consensus c ...... 3, Philadelphia, Pennsylvania.
@ast
Proceedings of the consensus c ...... 3, Philadelphia, Pennsylvania.
@en
P2860
P356
P1433
P1476
Proceedings of the consensus c ...... 3, Philadelphia, Pennsylvania.
@en
P2093
Gabriel N Hortobagyi
Gordon F Schwartz
P2860
P304
P356
10.1002/CNCR.20298
P407
P577
2004-06-01T00:00:00Z